US FDA Converges With Other Regulators On Insomnia Drug Warnings, But Broader Safety Disagreements Persist
Executive Summary
US FDA will add boxed warnings to insomnia drugs, bringing it in line with other regulators, even as a study in JAMA Internal Medicine study indicates that national drug authorities often disagree more broadly over when to issue safety advisories.
You may also be interested in...
US FDA Communications Post-Gottlieb: No Slow-Down In Statements, But Attribution Changes
Breakneck pace of press releases under former US FDA Commissioner Scott Gottlieb hasn’t abated in the early days of the Sharpless era – but the attribution has.
Merck Insomnia Drug Belsomra Has Warning That It Makes You Sleepy
Labeling includes impaired driving warnings at highest dose, but FDA cleared a range of lower doses – which the company argued during an advisory committee aren’t as effective.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.